ProShares Ultra Bloomberg Natural Gas

Direxion Daily TSLA Bull 1.5X Shares

United States Natural Gas

Direxion Daily 20+ Yr Trsy Bear 3X ETF

GraniteShares 1.25x Long Tesla Daily ETF

Direxion Daily Semicondct Bear 3X ETF

GraniteShares 1.5x Short NVDA Daily ETF

Direxion Daily FTSE China Bull 3X ETF

Direxion Technology Bear 3X Shares

Bank Of Montreal

ProShares UltraShort Bloomberg Natrl Gas

T-REX 2X Inverse Tesla Daily Target ETF

Direxion Daily 20+ Yr Trsy Bull 3X ETF

Direxion Daily Semicondct Bull 3X ETF

iShares Ethereum Trust ETF

ProShares Ultra Semiconductors

Direxion Daily Technology Bull 3X ETF

GraniteShares 1.5x Long NVDA Daily ETF

ProShares UltraPro QQQ

First Trust India Nifty 50 Equal Weight ETF

Siyata Mobile Inc. Common Shares

Eyenovia Inc. Common Stock

Edible Garden AG Incorporated Common Stock

D-Wave Quantum Inc. Common Shares

LOBO EV TECHNOLOGIES LTD. Ordinary shares

MicroAlgo Inc. Ordinary Shares

Pony AI Inc. American Depositary Shares

Mind Medicine (MindMed) Inc. Common Shares

COMPASS Pathways Plc American Depository Shares

ScanTech AI Systems Inc. Common stock

Protagenic Therapeutics Inc. Common Stock

NWTN Inc. Class B Ordinary Shares

ASP Isotopes Inc. Common Stock

Incannex Healthcare Limited American Depositary Shares

Brainstorm Cell Therapeutics Inc. Common Stock

Canaan Inc. American Depositary Shares

Trip.com Group Limited American Depositary Shares

SCWorx Corp. Common Stock

CoreWeave Inc. Class A Common Stock

Gevo Inc. Common Stock

Click here to get full coverage on PTGX: HC Wainwright & Co. Reiterates Buy Rating with $80 Target | PTGX Stock News - GuruFocus

PTGX: HC Wainwright & Co. Reiterates Buy Rating with $80 Target | PTGX Stock News  GuruFocus

PTGX: HC Wainwright & Co. Reiterates Buy Rating with $80 Target | PTGX Stock News - GuruFocus

Click here to get full coverage on Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday - Yahoo Finance

Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday  Yahoo Finance

Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday - Yahoo Finance

Click here to get full coverage on Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq

Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates  Nasdaq

Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq

Click here to get full coverage on Protagonist Hits Major Clinical Win: Phase 3 Trial Success Sets Stage for Two FDA Filings in 2025 - Stock Titan

Protagonist Hits Major Clinical Win: Phase 3 Trial Success Sets Stage for Two FDA Filings in 2025  Stock Titan

Protagonist Hits Major Clinical Win: Phase 3 Trial Success Sets Stage for Two FDA Filings in 2025 - Stock Titan

Click here to get full coverage on Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Shares Climb 44% But Its Business Is Yet to Catch Up - simplywall.st

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Shares Climb 44% But Its Business Is Yet to Catch Up  simplywall.st

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Shares Climb 44% But Its Business Is Yet to Catch Up - simplywall.st

Click here to get full coverage on Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out - Investor's Business Daily

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out  Investor's Business Daily

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out - Investor's Business Daily

Click here to get full coverage on Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - Yahoo Finance

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?  Yahoo Finance

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - Yahoo Finance

Click here to get full coverage on Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why - Nasdaq

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why  Nasdaq

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why - Nasdaq

Click here to get full coverage on First Oral IL-23 Drug Achieves 63% Response Rate in UC Trial - Stock Titan

First Oral IL-23 Drug Achieves 63% Response Rate in UC Trial  Stock Titan

First Oral IL-23 Drug Achieves 63% Response Rate in UC Trial - Stock Titan

Click here to get full coverage on Protagonist Therapeutics Insiders Sold US$5.1m Of Shares Suggesting Hesitancy - simplywall.st

Protagonist Therapeutics Insiders Sold US$5.1m Of Shares Suggesting Hesitancy  simplywall.st

Protagonist Therapeutics Insiders Sold US$5.1m Of Shares Suggesting Hesitancy - simplywall.st

Click here to get full coverage on Protagonist Therapeutics (PTGX) Reveals Promising Phase 3 Trial Results | PTGX Stock News - GuruFocus

Protagonist Therapeutics (PTGX) Reveals Promising Phase 3 Trial Results | PTGX Stock News  GuruFocus

Protagonist Therapeutics (PTGX) Reveals Promising Phase 3 Trial Results | PTGX Stock News - GuruFocus

Click here to get full coverage on Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance

Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain  Yahoo Finance

Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance

Click here to get full coverage on Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? - Yahoo Finance

Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment?  Yahoo Finance

Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? - Yahoo Finance

Click here to get full coverage on Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I - GuruFocus

Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I  GuruFocus

Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I - GuruFocus

Click here to get full coverage on Investors in Protagonist Therapeutics (NASDAQ:PTGX) have seen enviable returns of 397% over the past five years - Yahoo Finance

Investors in Protagonist Therapeutics (NASDAQ:PTGX) have seen enviable returns of 397% over the past five years  Yahoo Finance

Investors in Protagonist Therapeutics (NASDAQ:PTGX) have seen enviable returns of 397% over the past five years - Yahoo Finance

Click here to get full coverage on Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success - Yahoo Finance

Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success  Yahoo Finance

Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success - Yahoo Finance

Click here to get full coverage on News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat - Yahoo Finance

News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat  Yahoo Finance

News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat - Yahoo Finance

Click here to get full coverage on Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now - Yahoo Finance

Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now  Yahoo Finance

Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now - Yahoo Finance

Click here to get full coverage on Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025? - Yahoo Finance

Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025?  Yahoo Finance

Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025? - Yahoo Finance

Click here to get full coverage on The 4.2% return this week takes Protagonist Therapeutics' (NASDAQ:PTGX) shareholders five-year gains to 558% - simplywall.st

The 4.2% return this week takes Protagonist Therapeutics' (NASDAQ:PTGX) shareholders five-year gains to 558%  simplywall.st

The 4.2% return this week takes Protagonist Therapeutics' (NASDAQ:PTGX) shareholders five-year gains to 558% - simplywall.st

Click here to get full coverage on Protagonist Therapeutics: Q1 Earnings Snapshot - MySA

Protagonist Therapeutics: Q1 Earnings Snapshot  MySA

Protagonist Therapeutics: Q1 Earnings Snapshot - MySA

Click here to get full coverage on Protagonist (PTGX) Reports Q1 Revenue Below Expectations While Advancing Drug Pipeline | PTGX Stock News - GuruFocus

Protagonist (PTGX) Reports Q1 Revenue Below Expectations While Advancing Drug Pipeline | PTGX Stock News  GuruFocus

Protagonist (PTGX) Reports Q1 Revenue Below Expectations While Advancing Drug Pipeline | PTGX Stock News - GuruFocus

Click here to get full coverage on Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It (NASDAQ:PTGX) - Seeking Alpha

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It (NASDAQ:PTGX)  Seeking Alpha

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It (NASDAQ:PTGX) - Seeking Alpha

Click here to get full coverage on Why Is Protagonist Therapeutics Stock Trading Higher On Monday? - Benzinga

Why Is Protagonist Therapeutics Stock Trading Higher On Monday?  Benzinga

Why Is Protagonist Therapeutics Stock Trading Higher On Monday? - Benzinga

Click here to get full coverage on Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update | PTGX Stock News - GuruFocus

Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update | PTGX Stock News  GuruFocus

Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update | PTGX Stock News - GuruFocus

Click here to get full coverage on (PTGX) Investment Analysis - news.stocktradersdaily.com

(PTGX) Investment Analysis  news.stocktradersdaily.com

(PTGX) Investment Analysis - news.stocktradersdaily.com

Click here to get full coverage on Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting - Stock Titan

Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting  Stock Titan

Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting - Stock Titan

Click here to get full coverage on $PTGX stock is up 43% today. Here's what we see in our data. - Nasdaq

$PTGX stock is up 43% today. Here's what we see in our data.  Nasdaq

$PTGX stock is up 43% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on Protagonist Therapeutics (PTGX) Unveils Promising Data for Psori - GuruFocus

Protagonist Therapeutics (PTGX) Unveils Promising Data for Psori  GuruFocus

Protagonist Therapeutics (PTGX) Unveils Promising Data for Psori - GuruFocus

Click here to get full coverage on Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? - Yahoo Finance

Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?  Yahoo Finance

Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? - Yahoo Finance

Click here to get full coverage on The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey (PTGX) - Seeking Alpha

The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey (PTGX)  Seeking Alpha

The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey (PTGX) - Seeking Alpha

Click here to get full coverage on Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study - Benzinga

Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study  Benzinga

Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study - Benzinga

Click here to get full coverage on Protagonist Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Protagonist Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary  TradingView

Protagonist Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Click here to get full coverage on Protagonist Therapeutics, Inc SEC 10-Q Report - TradingView

Protagonist Therapeutics, Inc SEC 10-Q Report  TradingView

Protagonist Therapeutics, Inc SEC 10-Q Report - TradingView

Click here to get full coverage on Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More - Zacks Investment Research

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More  Zacks Investment Research

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More - Zacks Investment Research

Click here to get full coverage on 10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey

10 Best Cancer Stocks to Invest in for Long-Term Gains  Insider Monkey

10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey

Click here to get full coverage on Protagonist stock holds $80 target on positive study results - Investing.com

Protagonist stock holds $80 target on positive study results  Investing.com

Protagonist stock holds $80 target on positive study results - Investing.com

Click here to get full coverage on Truist Securities Adjusts Price Target on Protagonist Therapeutics to $76 From $60, Keeps Buy Rating - marketscreener.com

Truist Securities Adjusts Price Target on Protagonist Therapeutics to $76 From $60, Keeps Buy Rating  marketscreener.com

Truist Securities Adjusts Price Target on Protagonist Therapeutics to $76 From $60, Keeps Buy Rating - marketscreener.com

Click here to get full coverage on Protagonist Therapeutics rises as bowel disease drug succeeds mid-stage study - TradingView

Protagonist Therapeutics rises as bowel disease drug succeeds mid-stage study  TradingView

Protagonist Therapeutics rises as bowel disease drug succeeds mid-stage study - TradingView

Click here to get full coverage on Protagonist Therapeutics Stock Faces Mixed Signals - TipRanks

Protagonist Therapeutics Stock Faces Mixed Signals  TipRanks

Protagonist Therapeutics Stock Faces Mixed Signals - TipRanks

Click here to get full coverage on Protagonist Therapeutics CEO Sells Shares to Cover Tax Obligation - TradingView

Protagonist Therapeutics CEO Sells Shares to Cover Tax Obligation  TradingView

Protagonist Therapeutics CEO Sells Shares to Cover Tax Obligation - TradingView

Click here to get full coverage on J&J posts promising late-stage data for plaque psoriasis therapy developed with Protagonist - MSN

J&J posts promising late-stage data for plaque psoriasis therapy developed with Protagonist  MSN

J&J posts promising late-stage data for plaque psoriasis therapy developed with Protagonist - MSN

Click here to get full coverage on Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer - Benzinga

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer  Benzinga

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer - Benzinga

Click here to get full coverage on Protagonist Therapeutics director Waddill sells $217,000 in stock By Investing.com - Investing.com UK

Protagonist Therapeutics director Waddill sells $217,000 in stock By Investing.com  Investing.com UK

Protagonist Therapeutics director Waddill sells $217,000 in stock By Investing.com - Investing.com UK

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on 10 Firms Buck Market Bloodbath on Monday - Insider Monkey

10 Firms Buck Market Bloodbath on Monday  Insider Monkey

10 Firms Buck Market Bloodbath on Monday - Insider Monkey

Click here to get full coverage on Protagonist Therapeutics: Promising Pipeline and Strategic Partnerships Drive Buy Rating - TipRanks

Protagonist Therapeutics: Promising Pipeline and Strategic Partnerships Drive Buy Rating  TipRanks

Protagonist Therapeutics: Promising Pipeline and Strategic Partnerships Drive Buy Rating - TipRanks

Click here to get full coverage on Protagonist Therapeutics (PTGX) Stock Forecast and Price Target 2025 - MarketBeat

Protagonist Therapeutics (PTGX) Stock Forecast and Price Target 2025  MarketBeat

Protagonist Therapeutics (PTGX) Stock Forecast and Price Target 2025 - MarketBeat

Click here to get full coverage on Protagonist (PTGX) Up 14% on Licensing Deal With Takeda - Nasdaq

Protagonist (PTGX) Up 14% on Licensing Deal With Takeda  Nasdaq

Protagonist (PTGX) Up 14% on Licensing Deal With Takeda - Nasdaq

Click here to get full coverage on Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis - PR Newswire

Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis  PR Newswire

Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis - PR Newswire

Click here to get full coverage on Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis - PR Newswire

Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis  PR Newswire

Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis - PR Newswire

Click here to get full coverage on Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113 - PR Newswire

Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113  PR Newswire

Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113 - PR Newswire

Click here to get full coverage on Unusual Put Option Trade in Protagonist Therapeutics (PTGX) Worth $476.38K - Nasdaq

Unusual Put Option Trade in Protagonist Therapeutics (PTGX) Worth $476.38K  Nasdaq

Unusual Put Option Trade in Protagonist Therapeutics (PTGX) Worth $476.38K - Nasdaq

Click here to get full coverage on PTGX - Protagonist Ther Latest Stock News & Market Updates - Stock Titan

PTGX - Protagonist Ther Latest Stock News & Market Updates  Stock Titan

Protagonist Therapeutics Inc (PTGX)

Price Chart

Key Statistics

Technicals

About PTGX

Latest News

PTGX: HC Wainwright & Co. Reiterates Buy Rating with $80 Target | PTGX Stock News - GuruFocus

Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday - Yahoo Finance

Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq

Advanced Charts

Top Gainers

Top Losers